CARB-X FUNDS FACILE THERAPEUTICS TO DEVELOP A NEW TREATMENT TO PREVENT RECURRING C. DIFFICILE BACTERIAL INFECTIONS

  19 May 2020

CARB-X is awarding Facile Therapeutics, based in Belmont, California, USA, up to $1.26 million to develop a new orally bioavailable drug to treat recurring infections caused by Clostridium difficile. Facile could receive up to $17 million more in additional funding from CARB-X if the project achieves certain development milestones, for a potential total of $18.26 million.

“C. difficile represents an urgent global health threat and CARB-X is funding and supporting innovative R&D projects, like Facile’s Ebselen project, to address this growing threat,” said Erin Duffy, Chief of Research and Development of CARB-X, a non-profit partnership based at Boston University School of Law, dedicated to supporting early development antibacterial research around the world. “This is a terrific example of an attempt to repurpose a compound for use in the infectious-disease arena.  If successful and ultimately approved for use in patients, Facile’s project could represent tremendous progress in the prevention of recurrent C. difficile infections, and save many lives.”

Further reading: CARB-X
Author(s): CARB-X
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!